Affimed NV (NASDAQ:AFMD) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.14. The company had revenue of $1.37 million for the quarter, compared to analyst estimates of $1.20 million. Affimed NV had a negative return on equity of 57.35% and a negative net margin of 501.31%. The business’s quarterly revenue was down 17.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.19) earnings per share.
Shares of Affimed NV (NASDAQ:AFMD) traded down 7.778% during midday trading on Friday, reaching $2.075. The company’s stock had a trading volume of 535,265 shares. Affimed NV has a 1-year low of $1.65 and a 1-year high of $5.00. The company’s market capitalization is $91.17 million. The stock has a 50 day moving average of $2.43 and a 200-day moving average of $2.19.
A number of hedge funds and other institutional investors have recently modified their holdings of AFMD. Creative Planning boosted its position in shares of Affimed NV by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 15,000 shares in the last quarter. Muhlenkamp & Co. Inc. boosted its position in shares of Affimed NV by 150.8% in the third quarter. Muhlenkamp & Co. Inc. now owns 73,109 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 43,955 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Affimed NV during the third quarter worth $1,112,000. Nationwide Fund Advisors raised its position in shares of Affimed NV by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 479,007 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in shares of Affimed NV during the fourth quarter worth $1,322,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Affimed NV (AFMD) Announces Earnings Results” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/04/22/affimed-nv-afmd-announces-earnings-results.html.
Affimed NV Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
